VEGFA and hypertensive disorder: Hypertension, hand-foot syndrome, myelosuppression, and proteinuria are common TRAEs associated with VEGF/VEGFR inhibition, often reported in studies of angiogenesis inhibitors, such as apatinib (29), sorafenib (30), sunitinib (31), lenvatinib (32).